About Robert Finizio
Form D filings for Myosin Therapeutics in 2023 list Robert Finizio as director.
Form D filings also name Robert Finizio as an executive director at PleoPharma.
Robert Finizio reports to the SEC as a director, officer or major shareholder of 2 public companies: ZyVersa Therapeutics (ZVSA) and TherapeuticsMD (TXMD).
Robert Finizio first appears on SEC filings in 2011.
Experience
This experience comes from Robert Finizio's profile and from SEC filings. For roles taken from filings, the years are when the filings name Robert Finizio in the role, so the role may have started earlier or lasted longer.
MO
Mira Oncology Current
Board Member
2023 – Present
MC
MintPharma Capital Current
General Partner / Co-Founder
2022 – Present
Pleopharma, Inc. Current
Board Member (Executive Director)
2020 – Present · Phoenixville, PA
Develops a drug for adults experiencing cannabis withdrawal.
ZI
ZyVersa Therapeutics, Inc. Current
Member Board of Directors
2018 – Present · Public company (ZVSA)
BI
BioFlorida, Inc.
Previous Chairman of the Board
2022 – 2025
TI
TherapeuticsMD, Inc.
Previous Chief Executive Officer, Vice Chairman and Founder
2008 – 2022 · Public company (TXMD)
CA
CareFusion
Co-Founder
2000 – 2006
Key Colleagues at Startups
The people Robert Finizio works with at each company, as listed on that company's latest Form D.
Pleopharma, Inc. · Form D, Aug 10, 2026
KT
Kyle Tomlin
Director
GC
Ginger Constantine
Executive officer and director
SH
Sarah Hassan
Director
JC
Jay Constantine
Chief Medical Officer, Co-Founder and Director
MT
McInerney Timothy
Director
TP
Thomas Poche
Executive officer
DC
Daniel Cartwright
Chief Financial Officer
PB
Paul Bisaro
Director
TT
Tommy Thompson
Director
KM
Kyle Mowitz
Director
BS
Brij Sharma
Director
Myosin Therapeutics Inc. · Form D/A, Mar 24, 2023
PD
Patrick Griffin, Ph.D.
Director
DA
Dave Adams
Director
AR
Andrew Ritter
Director
CM
Courtney Miller
President and director
TK
Theodore Kamenecka
Director
JS
Jackson Streeter
Director